
Alaunos Therapeutics
(NASDAQ) TCRT
Alaunos Therapeutics Financials at a Glance
Market Cap
$4.86M
Revenue (TTM)
$3.00K
Net Income (TTM)
-$4.11M
EPS (TTM)
-$2.17
P/E Ratio
-0.92
Dividend
$0.00
Beta (Volatility)
1.44 (Average)
Dividend
$0.00
Beta (Volatility)
1.44 (Average)
Price
$2.05
Volume
4,343.723
Open
$1.99
Price
$2.05
Volume
4,343.723
Open
$1.99
Previous Close
$1.99
Daily Range
$1.98 - $2.01
52-Week Range
$1.67 - $6.20
Estimated Earnings Date
Aug 18, 2026
Dividend
$0.00
Beta (Volatility)
1.44 (Average)
Price
$2.05
Volume
4,343.723
Open
$1.99
Previous Close
$1.99
Daily Range
$1.98 - $2.01
52-Week Range
$1.67 - $6.20
Estimated Earnings Date
Aug 18, 2026
TCRT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Alaunos Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
1
CEO
Holger Weis, CPA
Website
www.alaunos.comHeadquarters
Houston, TX 77054, US
TCRT Financials
Key Financial Metrics (TTM)
Gross Margin
-63%
Operating Margin
-1382%
Net Income Margin
-1370%
Return on Equity
-350%
Return on Capital
-3%
Return on Assets
-2%
Earnings Yield
-1.09%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$4.86M
Shares Outstanding
2.44M
Volume
4.34K
Avg. Volume
17.09K
Financials (TTM)
Gross Profit
$5.00K
Operating Income
-$4.23M
EBITDA
-$4.23M
Operating Cash Flow
-$2.87M
Capital Expenditure
-$98.00K
Free Cash Flow
-$2.97M
Cash & ST Invst.
$1.39M
Total Debt
$0.00
Alaunos Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$8.00K
-500.0%
Gross Margin
0.00%
N/A
Market Cap
$4.86M
N/A
Market Cap/Employee
$4.86M
N/A
Employees
1
N/A
Net Income
-$1.01M
+6.2%
EBITDA
-$1.01M
+5.7%
Quarterly Fundamentals
Net Cash
$354.00K
+11.0%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-2.18%
N/A
Return on Invested Capital
-3.22%
N/A
Free Cash Flow
-$1.03M
-33.5%
Operating Cash Flow
-$1.03M
-33.5%







